Exisulind Versus Placebo After Surgical Removal of the Prostate
Completed · Phase 2
Conditions studied: Prostatic Neoplasms
In brief
This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.
Key facts
- Study ID
- NCT00166426
- Run by
- Mayo Clinic
- People needed
- 240
- Starts
- 2003-02-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2009-11-16
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.